AKT1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain AKT1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

AKT3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

ALK is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ATM is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATM status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].

ATR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ATRX is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATRX status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

AXL is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AXL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

BCL2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BCL6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRAF status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].

BRCA2 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [3].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRIP1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

BTRC is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

C11orf30 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain C11orf30 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CD79A is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

CDK4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN2A is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 0 are closed. Of the trials that contain CDKN2A status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CRKL status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DVL1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain EGFR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ERBB2 status and head and neck squamous cell carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (1 open) [3].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC5 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCA is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCA status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCB status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCC status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCD2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCF status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCG status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCI status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCL status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FANCM status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

FZD1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD10 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD2 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD4 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD7 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD8 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FZD9 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain HRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

KDR is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 5 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 2 are closed. Of the trials that contain KRAS status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

LRP5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP6 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MCPH1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MDM2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MET is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MET status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLF1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MLH3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MRE11A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MTAP is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTAP status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

MUTYH is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MUTYH status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

MYC is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain MYC status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NBN status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

NPM1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain NPM1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain NRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [3].

NTRK1 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PDGFRA status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].

PIK3AP1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3AP1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PIK3CA is an inclusion eligibility criterion in 4 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 2 are closed. Of the trials that contain PIK3CA status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3CG status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

PIK3R1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

PIK3R2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

PIK3R5 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R5 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

PMS1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PMS1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PMS2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain POLE status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R1A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R2A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 7 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 4 are closed. Of the trials that contain PTEN status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 4 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51C status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51D status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RICTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RNF43 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RNF43 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RPTOR status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

RSPO1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RSPO1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SLX4 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SMARCB1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain STAG2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

STK11 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain STK11 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain TP53 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

TSC2 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain TSC2 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [3].

WNT1 is an inclusion eligibility criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains WNT1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain XRCC1 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [3].